| Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia. | |
| | |
MedLine Citation:
|
PMID: 22986403 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
QUESTION In high-risk patients with dysglycemia, do n-3 fatty acid supplements reduce risk for cardiovascular (CV) events? METHODS DESIGN Randomized, 2 x 2 factorial, placebo-controlled trial (Outcome Reduction with an Initial Glargine Intervention [ORIGIN] trial). ClinicalTrials.gov NCT00069784. ALLOCATION {Concealed}*.† BLINDING Blinded† (patients, {health care providers, data collectors}‡, and event adjudication committee). FOLLOW-UP PERIOD Median 6.2 years. SETTING 573 clinical centers in 40 countries. PATIENTS 12 611 patients ≥ 50 years of age (mean age 64 y, 65% men) who had CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes mellitus. Exclusion criteria included glycated hemoglobin (HbA 1c) level ≥ 9%, coronary artery bypass graft in the past 4 years with no subsequent CV event, severe heart failure, or cancer that could affect survival. INTERVENTION n-3 fatty acid supplement, 1 g/d in a single capsule containing eicosapentaenoic acid (EPA), 465 mg, and docosahexaenoic acid (DHA), 375 mg ( n = 6319); or placebo containing olive oil ( n = 6292). Patients were also randomized to insulin glargine or standard care. OUTCOMES Primary outcome was CV death. Other outcomes included a composite CV endpoint (CV death, nonfatal myocardial infarction, or nonfatal stroke), all-cause mortality, and death from arrhythmia. 12 500 patients were needed to detect an 18.6% relative risk reduction from 1.5% per year in CV death at ≥ 6 years of follow-up (90% power, 2-sided α = 0.05). PATIENT FOLLOW-UP 99% for the primary outcome (intention-to-treat analysis). MAIN RESULTS Daily n-3 fatty acid supplements did not reduce risk for CV death, a composite CV endpoint, all-cause mortality, or death from arrhythmia more than placebo (Table). CONCLUSION In high-risk patients with dysglycemia, daily n-3 fatty acid supplements did not reduce cardiovascular events more than placebo.n-3 fatty acid supplements vs placebo in high-risk patients with dysglycemia§Outcomesn-3 fatty acidsPlaceboAt a median 6.2 yRRR (95% CI)||NNT (CI)CV death9.1%9.3%2% (-9 to 12)Not significantAll-cause mortality15.1%15.4%2% (-6 to 10)Not significantRRI (CI)||NNH (CI)Composite CV endpoint¶16.5%16.3%1% (-6 to 9)Not significantDeath from arrhythmia4.6%4.1%10% (-7 to 29)Not significant§CV = cardiovascular; other abbreviations defined in Glossary. RRR, RRI, and CI calculated from control event rates and hazard ratios in article.||Stratified by factorial allocation, baseline diabetes status, and CV history.¶Includes CV death, myocardial infarction (5.5% vs 5.1%, P = 0.28), or stroke (5.0% vs 5.4%, P = 0.32). |
| | |
Authors:
|
Ellis Lader |
Related Documents
:
|
16929253 - Protein evolution: causes of trends in amino-acid gain and loss. 16185863 - Novel and expanded jadomycins incorporating non-proteogenic amino acids. 12463373 - Capillary electrophoresis of cytochrome p-450 epoxygenase metabolites of arachidonic ac... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Annals of internal medicine Volume: 157 ISSN: 1539-3704 ISO Abbreviation: Ann. Intern. Med. Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-09-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: JC3-11 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Glargine did not reduce CV events more than standard care in patients with dysglycemia.
Next Document: CBT by telephone for depression improved adherence compared with face-to-face CBT in prima...